[
  {
    "ts": null,
    "headline": "Novo Nordisk Surges As Next-Gen Obesity Drug Outperforms",
    "summary": "Novo Nordisk Surges As Next-Gen Obesity Drug Outperforms",
    "url": "https://finnhub.io/api/news?id=fe221ce97276e6be8824900422af534ed79f47a1e23fbcfd197ae00334fb5db4",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737735426,
      "headline": "Novo Nordisk Surges As Next-Gen Obesity Drug Outperforms",
      "id": 132458795,
      "image": "",
      "related": "AMGN",
      "source": "DowJones",
      "summary": "Novo Nordisk Surges As Next-Gen Obesity Drug Outperforms",
      "url": "https://finnhub.io/api/news?id=fe221ce97276e6be8824900422af534ed79f47a1e23fbcfd197ae00334fb5db4"
    }
  },
  {
    "ts": null,
    "headline": "Amgen : North Carolina Ribbon Cutting Marks Important Milestone in Expansion to Meet Growing Demand for Amgen Medicines",
    "summary": "Amgen opened its newest cutting-edge drug substance facility in Holly Springs, North Carolina, with a ribbon cutting ceremony on January 24. The event took place less than two months after the biotech...",
    "url": "https://finnhub.io/api/news?id=39eb6f52bedffa4a870f7a833e0351dbac27f3cb9611f7f2359832ac0c324275",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737728285,
      "headline": "Amgen : North Carolina Ribbon Cutting Marks Important Milestone in Expansion to Meet Growing Demand for Amgen Medicines",
      "id": 132456067,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "Amgen opened its newest cutting-edge drug substance facility in Holly Springs, North Carolina, with a ribbon cutting ceremony on January 24. The event took place less than two months after the biotech...",
      "url": "https://finnhub.io/api/news?id=39eb6f52bedffa4a870f7a833e0351dbac27f3cb9611f7f2359832ac0c324275"
    }
  },
  {
    "ts": null,
    "headline": "Amgen : Update on Patent Litigation Related to Celltrion Denosumab Biosimilar Products",
    "summary": "Amgen Update on Patent Litigation Related to Celltrion Denosumab Biosimilar Products We are pleased to have reached resolution of our patent infringement litigation related to...",
    "url": "https://finnhub.io/api/news?id=59a3a651e5d9dcb1cbd37fe1675cb831f18443d3d09ee44e48b6035d0bc17dd7",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737723964,
      "headline": "Amgen : Update on Patent Litigation Related to Celltrion Denosumab Biosimilar Products",
      "id": 132455818,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "Amgen Update on Patent Litigation Related to Celltrion Denosumab Biosimilar Products We are pleased to have reached resolution of our patent infringement litigation related to...",
      "url": "https://finnhub.io/api/news?id=59a3a651e5d9dcb1cbd37fe1675cb831f18443d3d09ee44e48b6035d0bc17dd7"
    }
  },
  {
    "ts": null,
    "headline": "DIVO: Hard To Create A Case For Income Investors, Who Seek Covered-Call Exposure",
    "summary": "We critique investing in DIVO due to lack of strategic rationale, compares to other covered call names JEPQ, FEPI, JEPI. Read an analysis of DIVO ETF here.",
    "url": "https://finnhub.io/api/news?id=186a1022c2bee483b36c08732a4ebd26de2ea98f52382e54fada8c71ff8d99e4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737710100,
      "headline": "DIVO: Hard To Create A Case For Income Investors, Who Seek Covered-Call Exposure",
      "id": 132454884,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1462286293/image_1462286293.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "We critique investing in DIVO due to lack of strategic rationale, compares to other covered call names JEPQ, FEPI, JEPI. Read an analysis of DIVO ETF here.",
      "url": "https://finnhub.io/api/news?id=186a1022c2bee483b36c08732a4ebd26de2ea98f52382e54fada8c71ff8d99e4"
    }
  }
]